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A BS T R AC T
BACKGROUND

It is unknown whether warfarin or aspirin therapy is superior for patients with heart
failure who are in sinus rhythm.
METHODS

We designed this trial to determine whether warfarin (with a target international
normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better
treatment for patients in sinus rhythm who have a reduced left ventricular ejection
fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8).
The primary outcome was the time to the first event in a composite end point of
ischemic stroke, intracerebral hemorrhage, or death from any cause.
RESULTS

The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin
group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence
interval [CI], 0.79 to 1.10; P = 0.40). Thus, there was no significant overall difference
between the two treatments. In a time-varying analysis, the hazard ratio changed
over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but
this finding was only marginally significant (P = 0.046). Warfarin, as compared
with aspirin, was associated with a significant reduction in the rate of ischemic
stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per
100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P = 0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as
compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups
(0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P = 0.82).
CONCLUSIONS

Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin
and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was
offset by an increased risk of major hemorrhage. The choice between warfarin and
aspirin should be individualized. (Funded by the National Institute of Neurological
Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.)
n engl j med 366;20
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hronic heart failure is a major
cause of illness and death. Heart failure is
associated with a hypercoagulable state,
formation of left ventricular thrombus, and cerebral embolism.1,2 It is also associated with both
sudden death and death resulting from progressive
heart failure that may be caused by unrecognized
atherothrombotic events.3 As a result, there is a rationale for using oral anticoagulants to treat patients with chronic heart failure who are in sinus
rhythm. However, the role of oral anticoagulants
as compared with aspirin has not been clarified in
patients with chronic heart failure.4-6 Early studies
showed that anticoagulation reduced the rates of
embolic events and death, but many patients in
these trials had atrial fibrillation and clinically significant valvular heart disease, making interpretation of the results difficult.7-9 In retrospective
analyses of data from large trials involving patients with a reduced left ventricular ejection
fraction (LVEF), conflicting results have been reported.10-13 Unfortunately, these findings are of
limited value, since the use of anticoagulants was
not randomized or controlled, data were collected retrospectively, end points were not predefined
or standardized, and patients with atrial fibrillation were included.
Several prospective studies comparing oral anticoagulants with aspirin were too small to provide
conclusive evidence for the superiority of either
agent.14-16 In the Heart Failure Long-Term Antithrombotic Study (HELAS), 197 patients were randomly assigned to warfarin, aspirin, or placebo;
there was no significant difference among the
groups in the incidence of embolic events.14 In the
Warfarin/Aspirin Study in Heart Failure (WASH),
279 patients were randomly assigned to warfarin,
aspirin, or placebo; there was no significant difference among the groups in the composite end
point of death, stroke, or myocardial infarction,
but the rate of hospitalization was highest among
those receiving aspirin.15 The Warfarin and Antiplatelet Therapy in Chronic Heart Failure trial
(WATCH), which was the most recent and the
largest study, enrolled 1587 patients who were
randomly assigned to warfarin, aspirin, or clopidogrel, with a mean follow-up period of 1.9
years.16 The results of this trial, which was terminated prematurely owing to difficulties with
recruitment, suggested that there was a reduction in the rate of ischemic stroke with warfarin
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as compared with aspirin but showed an increase
in hospitalization for heart failure in the aspirin
group as compared with the warfarin group. The
Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial was designed to
compare the efficacy and safety of warfarin with
those of aspirin among a substantially larger number of patients, with the use of a double-blind,
randomized design.17

Me thods
Study Design and Oversight

We conducted a cooperative, double-blind, multicenter clinical trial at 168 centers in 11 countries.
The trial was sponsored by the National Institutes
of Health (NIH), with an independently funded
clinical coordinating center and statistical analysis
center. Warfarin and warfarin placebo were provided by Taro Pharmaceuticals U.S.A., and aspirin
and aspirin placebo by Bayer HealthCare. Neither
of these companies had any role in the design of
the study, the collection or analysis of the data, the
writing of the manuscript, or the decision to submit the manuscript for publication. The target international normalized ratio (INR) was 2.75, with
an acceptable target range of 2.0 to 3.5. To minimize variations in blood processing, blood samples
for determination of the INR were processed at
selected central laboratories. To confirm the accuracy of LVEF assessment, personnel at two core
echocardiography laboratories (in St. Louis and
New York) who were unaware of the treatment
assignments reviewed the echocardiographic studies. An independent end-point adjudication committee, whose members were unaware of the treatment assignments, adjudicated all primary and
secondary outcomes and major hemorrhages. The
trial protocol, available with the full text of this
article at NEJM.org, was approved by the institutional review board at each participating center.
The first two authors assume responsibility for the
completeness and accuracy of the data and analyses and for the fidelity of the study to the protocol.
Written informed consent was obtained from each
patient. Patient recruitment started in October
2002 and ended in January 2010. The maximum
follow-up time was 6 years, and the minimum was
1 year. An independent data and safety monitoring board appointed by the NIH monitored trial
operations.
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Study Patients

Eligible patients were 18 years of age or older and
had normal sinus rhythm, no contraindication to
warfarin therapy, and an LVEF of 35% or less as
assessed by quantitative echocardiography (or a
wall-motion index of ≤1.2) or as assessed by radionuclide or contrast ventriculography within
3 months before randomization. Patients who had
a clear indication for warfarin or aspirin were not
eligible. Patients in any New York Heart Association (NYHA) functional class were eligible, but patients in NYHA class I could account for no more
than 20% of the total number of patients undergoing randomization. Additional eligibility criteria
were a modified Rankin score of 4 or less (on a
scale of 0 to 6, with higher scores indicating more
severe disability), and planned treatment with a
beta-blocker, an angiotensin-converting–enzyme
(ACE) inhibitor (or, if the side-effect profile with
ACE inhibitors was unacceptable, with an angiotensin-receptor blocker), or hydralazine and nitrates.
Patients were ineligible if they had a condition that
conferred a high risk of cardiac embolism, such as
atrial fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated thrombus.
Study Medication

In the double-blind, double-dummy design, patients who were assigned to active warfarin received warfarin and placebo aspirin, and patients
assigned to active aspirin received aspirin and placebo warfarin.18 The statistical analysis center fabricated clinically plausible INR results for patients
in the aspirin group and provided these results to
the sites, along with the actual INR results for the
patients in the warfarin group, so that all the patients were treated as if they were receiving active
warfarin.
Follow-up

Follow-up was performed monthly by telephone or
in person at the time blood was obtained for determination of the INR, to assess adherence to the
study drug and to regulate INR values. A followup assessment in person was also conducted quarterly for a clinical evaluation and annually for a
detailed examination. All data were entered into
the Web-based communications interface that was
developed and managed by the statistical analysis
center.

n engl j med 366;20

Assessment of Outcomes and Major Adverse
Events

The primary outcome was the time to the first
event in a composite end point of ischemic stroke,
intracerebral hemorrhage, or death from any cause.
Stroke was defined as a clinically relevant new
lesion detected on computed tomography or magnetic resonance imaging (MRI) or, in the absence
of a new lesion, clinical findings that were consistent with the occurrence of clinical stroke and
that lasted for longer than 24 hours. The main
secondary outcome was the first event in a composite of the primary outcome, myocardial infarction, or hospitalization for heart failure. Major
hemorrhage was defined as intracerebral, epidural,
subdural, subarachnoid, spinal intramedullary, or
retinal hemorrhage; any other bleeding causing a
decline in the hemoglobin level of more than 2 g
per deciliter in 48 hours; or bleeding requiring
transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Minor hemorrhage was defined as any nonmajor hemorrhage.
Statistical Analysis

The primary null hypothesis was that the time to
the first event in the composite primary end point
(ischemic stroke, intracerebral hemorrhage, or
death from any cause) would not differ significantly between the group receiving warfarin therapy
and the group receiving aspirin therapy. The main
secondary null hypothesis was that the time to the
first event of the primary outcome, myocardial infarction, or hospitalization for heart failure would
not differ significantly between the two groups.
The original target sample size was 2860 patients, providing 89% power to test the primary
null hypothesis in the intention-to-treat population, with the use of a log-rank test and a twosided probability of a type I error of 5%, assuming
a hazard rate reduction of 17.82% in either group
as compared with the other, after adjustment for
use or nonuse of beta-blockers and allowance for
discontinuation of therapy, dropout, and crossover
(e.g., owing to the development of atrial fibrillation). In 2009, because of slow recruitment, a plan
was developed to stop recruitment in 2010 and to
extend the maximum follow-up time from 5 years
to 6 years, resulting in a projected sample size of
2303 and power of approximately 65%. The final
sample of 2305 patients yielded a sufficient number of outcomes for the study to have 69% power
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Table 1. Baseline Characteristics of the Study Participants, According to Treatment Group.*
Characteristic

Warfarin (N = 1142)

Aspirin (N = 1163)

61±11.6

61±11.1

North America

573 (50.2)

546 (46.9)

Europe

527 (46.1)

567 (48.8)

Age — yr
Location — no. (%)

Argentina

42 (3.7)

50 (4.3)

904/1140 (79.3)

936/1160 (80.7)

Non-Hispanic white

857/1140 (75.2)

876/1159 (75.6)

Non-Hispanic black

Male sex — no./total no. (%)
Race or ethnic group — no./total no. (%)†

166/1140 (14.6)

166/1159 (14.3)

Hispanic

85/1140 (7.5)

81/1159 (7.0)

Other

32/1140 (2.8)

36/1159 (3.1)

Height — cm

172±9.3

Weight — kg

172±9.2

86±19.6

87±19.3

29±5.9

29±6

Body-mass index‡
Mean
Distribution — no./total no. (%)
<25

294/1135 (25.9)

265/1149 (23.1)

25–30

426/1135 (37.5)

456/1149 (39.7)

>30

415/1135 (36.6)

428/1149 (37.2)

Blood pressure — mm Hg
Systolic

124±19.3

Diastolic
Pulse — beats/min

124±18.4

74±11.6

74±11.3

72±11.4

72±12.5

Hypertension — no./total no. (%)

671/1104 (60.8)

696/1128 (61.7)

Diabetes mellitus — no./total no. (%)

371/1138 (32.6)

351/1156 (30.4)

Atrial fibrillation — no./total no. (%)

44/1139 (3.9)

42/1156 (3.6)

Myocardial infarction — no./total no. (%)

549/1138 (48.2)

563/1156 (48.7)

Ischemic cardiomyopathy — no./total no. (%)

488/1138 (42.9)

503/1155 (43.5)

28/1139 (2.5)

24/1155 (2.1)

Current smoker

213/1138 (18.7)

195/1158 (16.8)

Former smoker

581/1138 (51.1)

599/1158 (51.7)

Never smoked

344/1138 (30.2)

364/1158 (31.4)

Current consumption, >2 oz/day

279/1140 (24.5)

293/1158 (25.3)

Previous consumption, >2 oz/day

250/1140 (21.9)

256/1158 (22.1)

Never consumed alcohol

611/1140 (53.6)

609/1158 (52.6)

<High school

490/1140 (43.0)

502/1155 (43.5)

High-school graduate or some college

487/1140 (42.7)

460/1155 (39.8)

College graduate or postgraduate

163/1140 (14.3)

193/1155 (16.7)

Pulmonary or other embolism — no./total no. (%)
Smoking status — no./total no. (%)

Alcohol consumption — no./total no. (%)

Educational level — no./total no. (%)

NYHA classification — no./total no. (%)§

1862

I

150/1137 (13.2)

165/1153 (14.3)

II

621/1137 (54.6)

646/1153 (56.0)

III

351/1137 (30.9)

329/1153 (28.5)

IV

15/1137 (1.3)

13/1153 (1.1)

n engl j med 366;20

nejm.org

may 17, 2012

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 29, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Warfarin and Aspirin in Patients with Heart Failure

Table 1. (Continued.)
Characteristic

Warfarin (N = 1142)

Ejection fraction — %
Distance covered on 6-minute walk — m¶
Prior stroke or TIA — no./total no. (%)

Aspirin (N = 1163)

25±7.5

25±7.5

346±147.3

356±152.5

155/1138 (13.6)

139/1157 (12.0)

Score on modified Rankin scale — no./total no. (%)‖
All patients
0

463/1133 (40.9)

489/1157 (42.3)

1

353/1133 (31.2)

359/1157 (31.0)

2

262/1133 (23.1)

266/1157 (23.0)

3

46/1133 (4.1)

40/1157 (3.5)

4

9/1133 (0.8)

3/1157 (0.3)

Patients with prior stroke or TIA
0

40/154 (26.0)

38/139 (27.3)

1

50/154 (32.5)

43/139 (30.9)

2

48/154 (31.2)

48/139 (34.5)

3

12/154 (7.8)

9/139 (6.5)

4

4/154 (2.6)

1/139 (0.7)

611/1047 (58.4)

632/1071 (59.0)

Medications — no./total no. (%)**
Aspirin††
Other antiplatelet agent††

32/428 (7.5)

40/461 (8.7)

Warfarin or other oral anticoagulant††

90/1142 (7.9)

89/1163 (7.7)

ACE inhibitor or ARB

1118/1136 (98.4)

1139/1157 (98.4)

Beta-blocker

1026/1136 (90.3)

1036/1158 (89.5)

Aldosterone blocker

406/666 (61.0)

407/679 (59.9)

Nitrate

284/1135 (25.0)

259/1158 (22.4)

Calcium-channel blocker

100/1135 (8.8)

103/1156 (8.9)

Diuretic

925/1136 (81.4)

930/1158 (80.3)

Statin

690/827 (83.4)

704/851 (82.7)

Device — no./total no. (%)
Pacemaker

141/1139 (12.4)

144/1156 (12.5)

Implantable cardioverter–defibrillator

212/1139 (18.6)

206/1156 (17.8)

*		 Plus–minus values are means ±SD. None of the differences between the warfarin group and the aspirin group were significant (P>0.05). Continuous variables were compared with the use of Student’s t-test. Binary categorical variables were compared with the use of Fisher’s exact test, and multicategory variables were compared with the use of standard chi-square
tests. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, and TIA transient ischemic attack.
†		 Race and ethnic group were self-reported separately and were combined for presentation.
‡		 The body-mass index is the weight in kilograms divided by the square of height in meters.
§		 The New York Heart Association (NYHA) classification groups patients with heart failure according to the extent of
limitation during physical activity. Class I indicates no limitation, and class IV severe limitation.
¶		 Data on the distance covered on a 6-minute walk were available for 2102 (1031 in the warfarin group and 1071 in the
aspirin group) of the 2305 patients (91.2%).
‖		 Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms and 6 indicating death. In this
study, the scores ranged from 0 to 4; a score higher than 4 was a protocol-specified criterion for exclusion.
** Data on medications were obtained from the case-report form at the screening visit.
†† Data on aspirin and other antiplatelet agents and warfarin or other oral anticoagulants are for the use of these medications before the patients underwent randomization.

to test the primary null hypothesis and 83% power
for the main secondary null hypothesis.
Both major study hypotheses were prespecified
and were tested according to the intention-to-treat
n engl j med 366;20

principle at a two-tailed alpha level of 0.05. For
the test of the primary null hypothesis, the statistical analysis plan prespecified the use of a logrank test to compare the cumulative incidence
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239 (20.9)

Myocardial infarction

Hospitalization for heart failure

6.79

0.80

0.11

0.57

4.43

203 (17.5)

31 (2.7)

2 (0.2)

41 (3.5)

158 (13.6)

435 (37.4)

323 (27.8)

2 (0.2)

55 (4.7)

263 (22.6)

320 (27.5)

no. of patients
(%)

5.67

0.87

0.06

1.14

4.41

12.15

8.02

0.05

1.36

6.52

7.93

unadjusted rate
of events/100
patient-yr

1.21 (0.998–1.47)

0.98 (0.58–1.64)

1.77 (0.32–9.88)

0.55 (0.32–0.96)

1.03 (0.81–1.30)

1.07 (0.93–1.23)

0.94 (0.80–1.10)

2.22 (0.43–11.66)

0.52 (0.33–0.82)

1.01 (0.85–1.20)

0.93 (0.79–1.10)

Hazard Ratio
(95% CI)†

0.053

0.93

0.51

0.03

0.83

0.33

0.44

0.35

0.005

0.91

0.40

P Value

* For the primary outcome, the number of patient-years was 4044.7 with warfarin and 4032.8 with aspirin; for the safety outcome, the number of patient-years was 4036.4 with warfarin
and 4026.6 with aspirin; and for the main secondary outcome, the number of patient-years was 3519.2 with warfarin and 3581.5 with aspirin.
† Hazard ratios were calculated with the use of Cox models (cause-specific models for components), with stratification according to site, NYHA class (I vs. II, III, or IV), and status with
respect to recent stroke.
‡ This analysis added intracranial hemorrhage to the components of the primary outcome.
§ Of the 622 patients who had a primary outcome, 241 (122 in the warfarin group and 119 in the aspirin group) had a myocardial infarction or were hospitalized for heart failure before
the primary outcome. For this reason, there are lower numbers of deaths, ischemic strokes, and intracerebral hemorrhages for the secondary outcome than for the primary outcome.

4 (0.4)
28 (2.5)

Intracerebral hemorrhage

20 (1.8)

156 (13.7)

12.70

7.61

0.12

0.72

6.63

7.47

unadjusted rate
of events/100
patient-yr

Aspirin (N = 1163)

of

Ischemic stroke

447 (39.1)

307 (26.9)

5 (0.4)

29 (2.5)

268 (23.5)

302 (26.4)

no. of patients
(%)

Warfarin (N = 1142)

n e w e ng l a n d j o u r na l

Death

Components§

Composite

Main secondary outcome: death, ischemic stroke, intracerebral hemorrhage,
myocardial infarction, or hospitalization for heart failure

Safety outcome: death, ischemic stroke, intracerebral hemorrhage, or intracranial hemorrhage‡

Intracerebral hemorrhage

Ischemic stroke

Death

Components

Composite

Primary outcome: death, ischemic stroke, or intracerebral hemorrhage

Outcome

Table 2. Primary, Safety, and Main Secondary Outcomes.*
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Patients with Primary Outcome (%)

curves in the treatment groups if log-minus-log
40
survival curves did not show a violation of the
proportional-hazards assumption and a Cox model
Aspirin
with time-varying hazard ratios if they did. Since
Warfarin
30
the log-minus-log survival curves crossed, we report the results of the log-rank test as the primary
analysis and, secondarily, the results from the Cox
model, which expresses the log-relative hazard
20
ratio as a linear function of follow-up time. A prespecified interim monitoring procedure was performed according to the method of Haybittle and
10
Peto, with conservative stopping boundaries for
the interim analyses of log-rank z scores in excess
of ±3.2905 (corresponding to a nominal two-tailed
0
P value of 0.001). Because very little type I error was
0
1
2
3
4
5
6
spent with this procedure, we report only the unYears
adjusted P values. Hazard ratios for individual
No. at Risk
components of the outcomes were obtained from
Aspirin
1163
1073
860
658
508
329
94
Warfarin
1142
1049
852
653
525
363
115
cause-specific proportional-hazards models with
or without time-varying coefficients, depending on
Figure 1. Cumulative Incidence of the Primary Outcome.
their statistical significance at an alpha level of
The primary outcome was the time to the first event in the composite end
0.05. To help weigh overall risks and benefits, we
point of ischemic stroke, intracerebral hemorrhage, or death from any cause.
conducted a post hoc safety analysis that added
intracranial hemorrhage to the components of the
(9.2%) entered the study with echocardiographic
primary outcome.
confirmation of LVEF or wall-motion-index values
at the local site, without the core laboratory review.
R e sult s
After a 6-week period of dose adjustment, paStudy Patients
tients in the warfarin group had an INR in the
From October 2002 through January 2010, a total of therapeutic range, defined as 2.0 to 3.5, for 62.6%
2305 patients were enrolled (1119 in the United of the follow-up time, as calculated with the use
States and Canada and 1186 in Europe and Ar- of a modification of the method of Rosendaal.19
gentina). The mean [±SD] follow-up time was INR values were below 2.0 for 27.1% of the total
3.5±1.8 years, and the total follow-up time was treatment time and above 3.5 for 10.3% of the
8225 patient-years. The clinical and demographic total treatment time. In the warfarin group, the
characteristics of the patients are shown in Table mean INR value during treatment was 2.5±0.95.
1. Survival status was known for 97.0% of the
patients. A total of 34 patients (1.5%) withdrew Outcomes
Overall, 622 of the 2305 patients (27.0%) had a
consent, and 35 (1.5%) were lost to follow-up.
primary outcome (531 deaths [85.4%], 84 ischemic
Laboratory Testing
strokes [13.5%], and 7 intracerebral hemorrhages
The mean LVEF for the entire study population [1.1%]) (Table 2). The rates of the primary outcome
was 24.7±7.5%, with no significant difference be- were 7.47 events per 100 patient-years in the warfatween the warfarin and aspirin groups. Echocar- rin group and 7.93 per 100 patient-years in the aspidiographic studies from 1854 of the 2305 patients rin group, with no significant difference between
in the study population (80.4%) were analyzed at the two groups (hazard ratio with warfarin, 0.93;
the core echocardiography laboratories; 1746 of 95% confidence interval [CI], 0.79 to 1.10; P = 0.40)
these patients (94.2%) had an LVEF of 35% or less (Fig. 1). A time-varying analysis with the use of a
or a wall-motion index of 1.2 or less. Baseline Cox model showed a small benefit of warfarin as
contrast angiography, radionuclide scanning, or compared with aspirin over time. The hazard ratio
MRI confirmed the eligibility of 239 of the 2305 decreased by a factor of 0.89 per year (95% CI,
patients (10.4%), and the remaining 212 patients 0.80 to 0.998; P = 0.046) and became borderline
n engl j med 366;20
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Figure 2. Hazard Ratios for the Primary Outcome with Warfarin, According to
Year of Follow-up.
Hazard ratios were estimated with the use of a stratified Cox model that expressed the log-relative hazard ratio as a linear function of follow-up time.
The hazard ratio decreased by a factor of 0.89 per year (95% confidence interval, 0.80 to 0.998; P = 0.046). I bars indicate 95% confidence intervals.

significant by year 4 (hazard ratio with warfarin,
0.76; P = 0.04) (Fig. 2).
In the entire patient population, there was a
constant and significant benefit with warfarin as
compared with aspirin with respect to the rate
of ischemic stroke (hazard ratio, 0.52; 95% CI,
0.33 to 0.82; P = 0.005) (Table 2). The two treatment groups did not differ significantly with respect to the rate of intracerebral hemorrhage. Patients in the warfarin group did not receive the
randomly assigned medication (and instead received open-label therapy) for 34% of the total
follow-up time, and patients in the aspirin group
did not receive the assigned medication for 32%
of the time. With respect to the main secondary
outcome (first event in the composite of death,
ischemic stroke, intracerebral hemorrhage, myocardial infarction, or hospitalization for heart
failure), there was no significant difference between the warfarin group and the aspirin group
(hazard ratio with warfarin, 1.07; 95% CI, 0.93
1866

n engl j med 366;20

of

m e dic i n e

to 1.23; P = 0.33). The rates of myocardial infarction and hospitalization for heart failure did not
differ significantly between the two groups, although there was a trend toward a higher rate of
hospitalization for heart failure in the warfarin
group (P = 0.053) (Table 2).
The rate of major hemorrhage was significantly
higher with warfarin than with aspirin (1.78 events
per 100 patient-years with warfarin vs. 0.87 per
100 patient-years with aspirin; adjusted rate ratio,
2.05; 95% CI, 1.36 to 3.12; P<0.001) (Table 3).
However, the rates of intracerebral and intracranial
hemorrhages combined did not differ significantly according to treatment group (0.27 events
per 100 patient-years in the warfarin group and
0.22 per 100 patient-years in the aspirin group,
P = 0.82). Major gastrointestinal bleeding occurred
more frequently in the warfarin group (0.94 events
per 100 patient-years vs. 0.45 per 100 patient-years
in the aspirin group, P = 0.01). Table S1 in the
Supplementary Appendix (available at NEJM.org)
shows the most frequent and the most clinically
relevant serious adverse events according to treatment group.

Discussion
The WARCEF trial was designed to determine
whether warfarin or aspirin is a better treatment
for patients with a reduced LVEF who are in sinus
rhythm. Previous studies either were retrospective
or lacked the power to adequately address this issue. As a result, there has been insufficient evidence to support any strong treatment recommendations regarding the use of warfarin or aspirin in
these patients. Our trial had a double-blind design
with sham INRs, similar to that used in the Warfarin–Aspirin Recurrent Stroke Study (WARSS,
NCT00027066), and used centralized INR processing centers to ensure that the INR data would be
of high quality.18,20
Our results show no significant overall difference between warfarin and aspirin therapies in
preventing the primary outcome. Although there
may have been a small benefit with warfarin
among patients followed for 4 or more years, it was
of borderline statistical significance and uncertain clinical significance. There was a consistent
and significant benefit of warfarin as compared
with aspirin with respect to the prevention of is
chemic stroke throughout the follow-up period.
This benefit was suggested in the WATCH trial
nejm.org
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Table 3. Rates of Hemorrhage and Death, According to Treatment Group.*
Event

Odds Ratio or Rate
Ratio (95% CI)†

P Value‡

263 (22.6)

1.05 (0.86–1.27)

0.66

4 (0.3)

1.84 (0.54–6.32)

0.38

7 (0.6)

0.71 (0.22–2.40)

0.77

Warfarin (N = 1142)

Aspirin (N = 1163)

268 (23.5)
7 (0.6)
5 (0.4)

Death as part of primary outcome — no. of patients (%)
From any cause
Related to hemorrhage§
Death after primary outcome — no. of patients (%)¶
After ischemic stroke
After intracerebral hemorrhage

2 (0.2)

2 (0.2)

0.98 (0.11–9.10)

1.00

66 (5.8)

31 (2.7)

2.21 (1.42–3.47)

<0.001

Intracerebral

5 (0.4)

2 (0.2)

2.52 (0.52–17.9)

0.29

Intracranial**

5 (0.4)

7 (0.6)

0.72 (0.22–2.43)

0.77

Gastrointestinal

37 (3.2)

16 (1.4)

2.35 (1.30–4.38)

0.005

Other

21 (1.8)

7 (0.6)

3.06 (1.26–7.57)

0.008

280 (24.5)

189 (16.3)

1.65 (1.34–2.05)

<0.001

Major hemorrhage — no. of patients (%)‖

Minor hemorrhage — no. of patients (%)
All hemorrhages††
Total no. of patient-yr

4044.7

4032.8

Major hemorrhage — no. of events (no./100 patient-yr)

72 (1.78)

35 (0.87)

2.05 (1.36–3.12)

<0.001

5 (0.12)

2 (0.05)

2.48 (0.51–17.6)

0.45

6 (0.15)

7 (0.17)

0.86 (0.29–2.85)

1.00

38 (0.94)

18 (0.45)

2.10 (1.19–3.70)

0.010

23 (0.57)

8 (0.2)

2.88 (1.30–6.94)

0.01

468 (11.6)

296 (7.34)

1.56 (1.34–1.81)

<0.001

Intracerebral
Intracranial**
Gastrointestinal
All other
Minor hemorrhage — no. of events (no./100 patient-yr)

*		 The maximum follow-up time was 74.3 months. Hemorrhages that occurred on the day of the primary event (death, ischemic stroke, or
intracerebral hemorrhage) are included.
†		 Odds ratios are shown for all categories with number and percent of patients; rate ratios are shown for all categories with number of
events and rate per 100 person-years. Odds ratios and rate ratios are conditional maximum-likelihood estimates, stratified according to
geographic location (North America, Europe, or Argentina). No test for heterogeneity of odds ratios or rate ratios across geographic locations was significant at the 0.05 level; the smallest P value for heterogeneity was 0.08 for the rate of minor hemorrhage.
‡		 P values for categories with number and percent of patients were calculated with the use of the exact test of two independent proportions,
stratified according to geographic location. P values for categories with number of events and rate per 100 patient-years were calculated
with the use of the exact conditional binomial test for two independent Poisson variables, stratified according to geographic location.
§		 Included are major hemorrhages that occurred within 30 days before the patient died.
¶		 These deaths are not primary end points and are not included in the total number of deaths in this table or in Table 2.
‖		 Included is the first or only hemorrhage for each patient.
** Intracranial hemorrhages include intracranial or spinal hemorrhages, subarachnoid hemorrhages, subdural or epidural hemorrhages, and
retinal hemorrhages.
†† Included are all hemorrhages that occurred in any patient.

and has now been confirmed in the WARCEF trial,
which included more patients and a longer followup period.16 However, the benefit was offset by the
increase in the incidence of major bleeding. The
relative reduction in the risk of ischemic stroke
with warfarin among the patients in our study,
who had heart failure, is similar to that observed
among patients with atrial fibrillation.21 However,
the absolute risk of ischemic stroke among patients with a low LVEF who are in sinus rhythm
is significantly lower than that among patients
with atrial fibrillation.16
n engl j med 366;20

With respect to the main secondary outcome,
which included myocardial infarction and hospitalization for heart failure, in addition to the
primary outcome, there was no significant difference between the warfarin group and the aspirin
group. There was a trend toward an increased rate
of hospitalization for heart failure in the warfarin
group, a finding that is in direct contrast to the
results of the WASH and WATCH trials, which suggested an increased rate of hospitalization for
heart failure among patients receiving aspirin.15,16
There has been speculation that aspirin may innejm.org
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terfere with prostaglandin synthesis, leading to
a reduced effectiveness of ACE inhibition.22,23 In
our trial, however, no increase in the rate of
hospitalization for heart failure was seen in the
aspirin group as compared with the warfarin
group, even though a large proportion of patients
in the aspirin group were treated with an ACE
inhibitor.
In the warfarin group, the INR was in the
therapeutic range of 2.0 to 3.5 for 63% of the
total treatment time. We set the INR target above
that used in trials involving patients with atrial
fibrillation, because among trials involving patients who had had a myocardial infarction,
those with higher INR targets and values showed
the superiority of warfarin over aspirin, whereas
those with lower INR targets and values did
not.24,25 In our study, patients received either warfarin or aspirin and did not take both medications. The side-effect profile in the case of both
warfarin and aspirin was generally acceptable,
and there was a low rate of intracerebral hemorrhage. The rate of major hemorrhage was significantly increased with warfarin therapy but was
lower than that seen in the warfarin group in
recent trials involving patients with atrial fibrillation and similar to that seen in the WARSS and
WATCH trials.16,20,26,27
The limitations of our study include the smallerthan-anticipated number of patients enrolled, and,
given the variable length of follow-up, the relatively small numbers of patients who were still
being followed in years 5 and 6. The time in the
therapeutic range among patients in the warfarin
group was relatively low at 63%. In addition, in
both groups, there was a substantial portion of
follow-up time during which the patients did not
receive the assigned study treatment. However, this
duration was similar in the two treatment groups,
thus minimizing any bias. Since newer antithrombotic agents, as compared with warfarin, are easier
to administer and may be associated with better
long-term adherence to therapy, they may increase
the time in the therapeutic range and reduce the
time during which patients do not receive the
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assigned therapy.26-28 If so, they may prove to be
more effective than warfarin or aspirin.
In summary, this trial showed no significant
overall difference between warfarin and aspirin
with respect to the primary outcome of death,
ischemic stroke, or intracerebral hemorrhage.
However, among patients followed for 4 or more
years, there may have been a small benefit, of
uncertain clinical significance, with warfarin.
Warfarin was associated with a reduction in the
risk of ischemic stroke throughout the follow-up
period. Given the finding that warfarin did not
provide an overall benefit and was associated with
an increased risk of bleeding, there is no compelling reason to use warfarin rather than aspirin in
patients with a reduced LVEF who are in sinus
rhythm.
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